このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

代謝不全関連脂肪性肝疾患(MAFLD)に関連する慢性腎臓病の病態と経口セマグルチドの治療反応性

代謝機能障害関連脂肪性肝疾患 (MAFLD) に関連する慢性腎臓病の病因と経口セマグルチドの治療反応 - 無作為化比較試験

This project aims to investigate how Chronic Kidney Disease (CKD) develops and progresses in patients who also have Non-Alcoholic Fatty Liver Disease (NAFLD) and to evaluate whether oral semaglutide (a GLP-1 receptor agonist) can slow or prevent this progression.

NAFLD and CKD frequently coexist due to shared mechanisms such as insulin resistance, inflammation, oxidative stress, dyslipidemia, and metabolic syndrome. Because of these overlapping pathways, a single therapy targeting both organs may offer major benefits.

Semaglutide is known to reduce liver fat, improve inflammation and fibrosis, promote weight loss, and provide renal protection. This project will test whether adding oral semaglutide to standard care leads to better kidney and liver outcomes than standard care alone.

The study is designed as a randomised controlled trial conducted at ILBS, enrolling adults having NAFLD with CKD (with specific eGFR and albuminuria criteria). Participants will be followed for 2 years, with regular assessment of kidney function (eGFR, ACR), liver health (FibroScan, ALT/AST), metabolic parameters, and cardiovascular outcomes.

A parallel animal study in mice with diet-induced fatty liver disease will validate mechanistic findings through liver and kidney histology, gene expression, metabolic tests, and biochemical markers after semaglutide treatment.

Expected outcome: To demonstrate that semaglutide slows CKD progression and improves NAFLD, supporting its use as a therapeutic option for patients with coexisting both conditions.

調査の概要

詳細な説明

NAFLD and metabolic syndrome have emerged as significant health concerns globally, with substantial implications for kidney health.The interplay between NAFLD, metabolic syndrome, and CKD necessitates a comprehensive understanding of the underlying mechanisms and shared pathogenic pathways. Their shared risk factors, molecular mechanisms, and genetic predisposition represent the basis for this relationship.

Accordingly, treatment approaches with combined efficacy in NAFLD and chronic renal impairment are expected to positively impact the natural history of this deleterious interaction.

GLP1-R agonists GLP1-R agonists (GLP1-RAs) are novel potent antidiabetic agents with proven efficacy in reducing major adverse cardiovascular events. Besides their glucose-lowering action, their beneficial hepatic effects may be related to the influence on the AMPK/mTOR pathway. Semaglutide was associated with significant decreases in body weight, alanine aminotransferase, liver steatosis, and stiffness.GLP1-RAs may also improve histologic features on NAFLD, such as liver fat deposition, steatohepatitis, and fibrosis. GLP1-RAs have shown benefits in preventing the development or halting the progression of CKD. It also promotes antioxidative and anti-inflammatory actions may be among the determining factors in this renoprotective effect, together with weight loss, blood pressure, and glucose-lowering.

Primary objective-To measure the progression of CKD and NAFLD in Semaglutide treated group versus non treated group.

Secondary objectives-1.To conduct animal model studies to confirm the primary objective by performing the liver and renal histology.

Study Population-All patients diagnosed to have NAFLD with or without DM Type2 with CKD(GFR<60 ML/MIN AND ALBUMINURIA (>330 MG/MMOL)will be included in the study.

STUDY PLAN Type of study-Randomised Control Trial(RCT) Study period-3 years Intervention-adding oral semaglutide once a day (starting from 3mg to 14 mg ).we will start from 3mg once a day and go upto 14 mg once a day . Control arm-patients receiving standard of care.

Statistical analysis: Categorical values were reported as numbers, frequencies and percentages. Continuous data was reported as median and interquartile range (IQR) or mean with standard deviation. Chi square/Chi square with yate's correction/Fisher test was used for comparing categorical values depending on the sample size. For comparing continuous data, unpaired t-test or Mann Whitney was used as appropriate16 was used for statistical analysis. A p-value of below 0.05 was adapted as a value of statistical significance for the purpose of this study.Intension to treat and per protocol analysis will be done and any adverse event will be reported.

ANIMAL MODEL Male C57BL/6J mice (6 weeks old) are selected for the study Mice will be induced to liver disease by feeding a rodent diet with 58 Kcal% fat and sucrose (D12331- Research diets) for 20- 32 weeks and Mice on a standard chow diet will be included as controls. 6-week-old mice will be fed with 50% supplementation of a High-fat diet with standard chow diet for acclimatization for period of two weeks. Post which a complete high fat diet will be administered.

To reflect the disease state at the start of treatment, animals will be sacrificed from both groups. Histology for liver and kidney will be performed at dose start (baseline group), other endpoints and biochemical parameters will also be analyzed at this point.

Oral animal equivalent dose will be calculated using known human dose of Semaglutide. Oral semaglutide pills will be crushed into powder form and resuspended in distilled water for oral gavage. Semaglutide or vehicle (Distilled water/ Normal saline) will be administered orally daily for 8-12 weeks, while body weight, food and water consumption will be monitored daily. Weekly Insulin tolerance test and glucose tolerance test will be performed from the start of 20th weeks to analyze insulin resistance and hyperglycemia in mice model.

At study termination, blood sampled via retro-orbital will be collected for analysis of liver enzymes, plasma lipids (ALT, AST, TG and TC), serum urea, creatinine, and blood urea nitrogen. Urine will be collected to measure Albumin and creatinine using commercially available ELISA kits. Collected plasma samples will be used to measure levels of Adiponectin, leptin, resistin and ghrelin using commercially available ELISA kits. Animals will be euthanized using ketamine and xylazine cocktail, and liver and renal tissues will be collected weighed and subjected to histology, gene expression and other biochemical parameters for further study and inference.

These expected deliverable aim to demonstrate the efficacy of Semaglutide in slowing the progression of CKD and NAFLD, validated through both clinical and preclinical studies, thereby supporting its potential use as a therapeutic option for these conditions.

研究の種類

介入

入学 (推定)

90

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • National Capital Territory of Delhi
      • New Delhi、National Capital Territory of Delhi、インド、110070
        • 募集
        • Institute of Liver and Biliary Sciences
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • 1.Age above or equal to 18 years at the time of signing informed consent. 2.Diagnosed with type 2 diabetes mellitus 3.HbA1c less than or equal to 10% (less than or equal to 86 mmol/mol) 4.Renal impairment defined either by:
  • serum creatinine-based eGFR greater than or equal to 50 and less than or equal to 75 mL/min/1.73 m^2 (CKD-EPI) and UACR greater than 300 and less than 5000 mg/g or
  • serum creatinine-based eGFR greater than or equal to 25 and less than 50 mL/min/1.73 m^2 (CKD-EPI) and UACR greater than 100 and less than 5000 mg/g 5.Treatment with maximum labelled or tolerated dose of a reninangiotensin-aldosterone system (RAAS) blocking agent including an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is contraindicated or not tolerated. Treatment dose must be stable for at least 4 weeks prior to the date of the laboratory assessments used for determination of the inclusion criteria for renal impairment and kept stable until screening.

Exclusion Criteria:

  1. Documented causes of chronic liver disease other than non-alcoholic fatty liver disease (NAFLD)

  2. Positive HBsAg, positive anti-HIV, positive HCV RNA at screening (V2A) or any known presence of HCV RNA or HBsAg within 2 years of screening (V2A).

  3. Presence or history of ascites, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis or liver transplantation at randomisation.

  4. Known or suspected excessive consumption of alcohol (greater than 20 g/day for women or greater than 30 g/day for men) or alcohol dependence (assessed by the Alcohol Use Disorders Identification Test (AUDIT questionnaire)).

  5. Treatment with vitamin E (at doses greater than or equal to 800 IU/day) or pioglitazone or medications approved for treatment of NASH which has not been at a stable dose in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, treatment should be at a stable dose from time of biopsy until screening.

  6. Treatment with GLP-1 RAs in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, any treatment with GLP-1 RAs from time of biopsy until screening (V2A).

  7. Treatment with glucose-lowering agent(s) (other than GLP-1 RAs), lipid-lowering medication or weight loss medication not stable in the opinion of the investigator in the period from 90 days prior to the screening visit (V2A). In addition, for subjects with historical liver biopsies taken more than 90 days prior to screening, treatment should be at a stable dose in the opinion of the investigator from time of biopsy until screening.

  8. Congenital or hereditary kidney diseases including polycystic kidney disease, autoimmune kidney diseases including glomerulonephritis or congenital urinary tract malformations

  9. Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within 60 days prior to the day of screening.

  10. Presently classified as being in New York Heart Association (NYHA) Class IV heart failure

  11. Planned coronary, carotid or peripheral artery revascularisation

  12. Current (or within 90 days) chronic or intermittent haemodialysis or peritoneal dialysis 13 Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupildilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.

    -

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Standard Medical Treatment (SMT)

Control arm : Participants in this arm will receive Placebo with Standard Medical Treatment (SMT).

Placebo will be given in the same manner.

Standard medical treatment-

  1. Lifestyle first - weight loss , caloric restriction, increased aerobic + resistance exercise, treat obesity and metabolic syndrome.

  2. Optimize blood-pressure control and use RAAS blockade when indicated (ACE inhibitor or ARB) to reduce albuminuria and slow CKD progression .

  3. Treat dysglycaemia and favour drug classes with kidney + liver benefit when appropriate

    • SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) - recommended for people with T2D + CKD
    • GLP-1 receptor agonists (e.g., semaglutide)
  4. Lipid management / statins - treat according to CV risk

  5. Consider established liver-directed agents when appropriate

  6. Pioglitazone (thiazolidinedione) and vitamin-E

  7. Standard CKD supportive care - salt and fluid management, correction of metabolic acidosis, anaemia and mineral bone abnormalities as per CKD stage; immunize and address CV risk factors aggressively

  8. Avoid hepatotoxic drugs / review medications

実験的:Semaglutide with Standard Medical Treatment

Semaglutide with Standard Medical Treatment: Participants in this arm will receive Standard medical treatment and oral semaglutide starting from 3mg dose daily that gradually increases upto 14mg dose daily for 6 months.

Standard medical treatment-

  1. Lifestyle first - weight loss , caloric restriction, increased aerobic + resistance exercise, treat obesity and metabolic syndrome.

  2. Optimize blood-pressure control and use RAAS blockade when indicated (ACE inhibitor or ARB) to reduce albuminuria and slow CKD progression .

  3. Treat dysglycaemia and favour drug classes with kidney + liver benefit when appropriate

    • SGLT2 inhibitors (dapagliflozin, empagliflozin, canagliflozin) - recommended for people with T2D + CKD
    • GLP-1 receptor agonists (e.g., semaglutide)
  4. Lipid management / statins - treat according to CV risk

  5. Consider established liver-directed agents when appropriate

  6. Pioglitazone (thiazolidinedione) and vitamin-E

  7. Standard CKD supportive care - salt and fluid management, correction of metabolic acidosis, anaemia and mineral bone abnormalities as per CKD stage; immunize and address CV risk factors aggressively

  8. Avoid hepatotoxic drugs / review medications

GLP1-R agonists GLP1-R agonists (GLP1-RAs) are novel potent antidiabetic agents with proven efficacy in reducing major adverse cardiovascular events. Besides their glucose-lowering action, their beneficial hepatic effects may be related to the influence on the AMPK/mTOR pathway. Semaglutide was associated with significant decreases in body weight, alanine aminotransferase, liver steatosis, and stiffness.GLP1-RAs may also improve histologic features on NAFLD, such as liver fat deposition, steatohepatitis, and fibrosis. GLP1-RAs have shown benefits in preventing the development or halting the progression of CKD. It also promotes antioxidative and anti-inflammatory actions may be among the determining factors in this renoprotective effect, together with weight loss, blood pressure, and glucose-lowering.

この研究は何を測定していますか?

主要な結果の測定

結果測定
時間枠
試験開始時から持続的な推定糸球体濾過量(eGFR)の50%以上の低下、末期腎不全(ESRD)への到達、腎疾患による死亡、または心血管疾患による死亡のいずれかを複合一次アウトカム事象として定義した、その初回発生までの時間。
時間枠:3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月

二次結果の測定

結果測定
時間枠
eGFRの年間変化率(慢性腎臓病疫学共同研究(CKD-EPI))
時間枠:3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
複合心血管主要有害心血管イベント(MACE)エンドポイントの初発までの時間。MACEは以下で構成される:非致死性心筋梗塞、非致死性脳卒中、心血管(CV)死亡
時間枠:3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
全死因死亡までの時間
時間枠:3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
eGFRと蛋白尿の変化。
時間枠:3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
eGFR(CKD-EPI)の年間変化率(慢性eGFRスロープ)
時間枠:3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
eGFR(CKD-EPI)およびシスタチンCの変化
時間枠:3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
アルブミン・クレアチニン比(ACR)の変化
時間枠:3ヶ月、6ヶ月、12ヶ月、18ヶ月および24ヶ月
3ヶ月、6ヶ月、12ヶ月、18ヶ月および24ヶ月
体重の変化
時間枠:3か月、6か月、12か月、18か月および24か月
3か月、6か月、12か月、18か月および24か月
HBA1cの変化
時間枠:3か月、6か月、12か月、18か月、24か月
3か月、6か月、12か月、18か月、24か月
収縮期血圧および拡張期血圧の変化
時間枠:3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
低血糖エピソードの数
時間枠:3ヵ月、6ヵ月、12ヵ月、18ヵ月、24ヵ月
3ヵ月、6ヵ月、12ヵ月、18ヵ月、24ヵ月
動物モデルにおける肝組織学の変化(Alpha-SMA、Col-1による評価)
時間枠:4、8、16、24週間
4、8、16、24週間
SGOT/SGPTによって評価された動物モデルにおける肝臓組織学的変化。
時間枠:4,8,16,24週間
4,8,16,24週間
UPCR、GFR、クレアチニンクリアランスにより評価された動物モデルにおける腎組織学の変化。
時間枠:4,8,16,24週間
4,8,16,24週間
FITC-シニストリンクリアランス、シスタチン-Cにより評価された動物モデルにおける腎組織の変化
時間枠:4,8,16,24週間
4,8,16,24週間
脂肪性肝炎の解消と肝線維症の改善(はい/いいえ)
時間枠:3ヶ月、6ヶ月、12ヶ月、18ヶ月および24ヶ月
3ヶ月、6ヶ月、12ヶ月、18ヶ月および24ヶ月
transient elastography (FibroScan®) により評価された肝硬度値の変化
時間枠:3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
ELF(強化肝線維化)スコアの変化
時間枠:3か月、6か月、12か月、18か月、24か月
3か月、6か月、12か月、18か月、24か月
ALT/ASTの変化
時間枠:3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
一過性弾性測定法(FibroScan)によるCAP(Controlled Attenuation Parameter)値の変化
時間枠:3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
FAST(FibroScan-AST)スコアの変化
時間枠:3か月、6か月、12か月、18か月、24か月
3か月、6か月、12か月、18か月、24か月
hsCRP(高感度C反応性タンパク質)で評価される炎症の変化
時間枠:3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
3ヶ月、6ヶ月、12ヶ月、18ヶ月、24ヶ月
トリグリセリド/LDLの変化
時間枠:3か月、6か月、12か月、18か月、24か月
3か月、6か月、12か月、18か月、24か月

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年5月25日

一次修了 (推定)

2028年12月31日

研究の完了 (推定)

2028年12月31日

試験登録日

最初に提出

2025年12月15日

QC基準を満たした最初の提出物

2026年1月29日

最初の投稿 (実際)

2026年2月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月9日

QC基準を満たした最後の更新が送信されました

2026年11月5日

最終確認日

2025年12月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する